OUR PIPELINE

Indication

IND-enabling

*Phase I/II

BLA

Partner

Lenzilumab

Break CAR-T Efficacy/Toxicity Linkage
Lenz prophylaxis as sequenced therapy with Yescarta in r/r DLBCL

ZUMA-19

Prevention/Treatment of Acute GvHD

Allogeneic Hematopoietic Stem Cell Transplant

CAR-Ts

FasterCARs

Novel multiple  combination CARs w/ GM-CSF k/o: increase efficacy and safety for hematologic & solid cancers

EphA3 – CAR 
with GM-CSF k/o for hematologic & solid cancers

EMR1 – CAR
with GM-CSF k/o for eosinophilic disorders

*Potential for Breakthrough designation and accelerated path to approval following successful completion of phase I/II studies, similar to Yescarta and Kymriah

©2019 Humanigen, Inc.  All rights reserved